Boehringer Ingelheim Advances BI 3034701 into Phase II Obesity Trial
INGELHEIM, Germany, July 16, 2026 Boehringer Ingelheim has initiated a Phase II clinical trial evaluating BI 3034701, an investigational...
survodutide
Advertisement
Boehringer Reports Strong H1 2026 Sales
INGELHEIM, Germany, July 15, 2026 Boehringer Ingelheim reported strong financial and operational performance for the first half of 2026,...
Boehringer’s Survodutide Delivers Major Metabolic Benefits
INGELHEIM, Germany – June 7, 2026 Boehringer Ingelheim has reported positive Phase III results for its investigational glucagon/GLP-1 dual...
Zealand Pharma Highlights Positive Phase III Survodutide Results in Obesity
COPENHAGEN, Denmark, June 7, 2026 Zealand Pharma A/S announced that its partner Boehringer Ingelheim presented detailed results from the...
Boehringer Survodutide Shows 16.6% Weight Loss in Phase III
INGELHEIM, GERMANY, April 28, 2026 Boehringer Ingelheim has announced positive Phase III results for its investigational dual agonist survodutide,...
Advertisement
